These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33396632)

  • 1. NLRP1 Functions Downstream of the MAPK/ERK Signaling via ATF4 and Contributes to Acquired Targeted Therapy Resistance in Human Metastatic Melanoma.
    Zhai Z; Vaddi PK; Samson JM; Takegami T; Fujita M
    Pharmaceuticals (Basel); 2020 Dec; 14(1):. PubMed ID: 33396632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammasome Sensor NLRP1 Confers Acquired Drug Resistance to Temozolomide in Human Melanoma.
    Zhai Z; Samson JM; Yamauchi T; Vaddi PK; Matsumoto Y; Dinarello CA; Ravindran Menon D; Fujita M
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32899791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
    Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
    Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
    Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
    Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma.
    Zhai Z; Liu W; Kaur M; Luo Y; Domenico J; Samson JM; Shellman YG; Norris DA; Dinarello CA; Spritz RA; Fujita M
    Oncogene; 2017 Jul; 36(27):3820-3830. PubMed ID: 28263976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase.
    Kosnopfel C; Sinnberg T; Sauer B; Niessner H; Schmitt A; Makino E; Forschner A; Hailfinger S; Garbe C; Schittek B
    Oncotarget; 2017 May; 8(22):35761-35775. PubMed ID: 28415756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
    J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
    Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
    Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma.
    Zecena H; Tveit D; Wang Z; Farhat A; Panchal P; Liu J; Singh SJ; Sanghera A; Bainiwal A; Teo SY; Meyskens FL; Liu-Smith F; Filipp FV
    BMC Syst Biol; 2018 Apr; 12(1):33. PubMed ID: 29615030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway.
    Benito-Jardón L; Díaz-Martínez M; Arellano-Sánchez N; Vaquero-Morales P; Esparís-Ogando A; Teixidó J
    Cancer Res; 2019 May; 79(9):2244-2256. PubMed ID: 30833419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
    Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad.
    Eisenmann KM; VanBrocklin MW; Staffend NA; Kitchen SM; Koo HM
    Cancer Res; 2003 Dec; 63(23):8330-7. PubMed ID: 14678993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PKCδ regulates death receptor 5 expression induced by PS-341 through ATF4-ATF3/CHOP axis in human lung cancer cells.
    Xu L; Su L; Liu X
    Mol Cancer Ther; 2012 Oct; 11(10):2174-82. PubMed ID: 22848091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways Inhibition.
    El Zaoui I; Bucher M; Rimoldi D; Nicolas M; Kaya G; Pescini Gobert R; Bedoni N; Schalenbourg A; Sakina E; Zografos L; Leyvraz S; Riggi N; Rivolta C; Moulin AP
    Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2764-2772. PubMed ID: 31247083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
    Wang AX; Qi XY
    IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells.
    Zhao K; Lu Y; Chen Y; Cheng J; Zhang W
    Exp Cell Res; 2020 May; 390(2):111942. PubMed ID: 32173467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma.
    Cui H; Wang Q; Miller DD; Li W
    Front Pharmacol; 2021; 12():637098. PubMed ID: 33841154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.